Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial
Titel:
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial
Auteur:
Naidoo, Jarushka Vansteenkiste, Johan F. Faivre-Finn, Corinne Özgüroğlu, Mustafa Murakami, Shuji Hui, Rina Quantin, Xavier Broadhurst, Helen Newton, Michael Thiyagarajah, Piruntha Antonia, Scott J.